Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies
Supportive Care in Cancer, Volume 23, No. 8, Year 2015
Notification
URL copied to clipboard!
Description
Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index (DLQI), and DIELH-24) and two were symptom-specific (functional assessment of cancer therapy-epidermal growth factor receptor inhibitor-18 (FACT-EGFRI-18) and hand-foot syndrome 14 (HFS-14)). Conclusions: While there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.
Authors & Co-Authors
Chan, Alexandre
Singapore, Singapore City
National University of Singapore
Cameron, Michael C.
United States, Tampa
Morsani College of Medicine
Garden, Benjamin
United States, New York
Memorial Sloan-kettering Cancer Center
Boers-Doets, Christine B.
Netherlands, Wormer
Impaqtt Foundation
Netherlands, Leiden
Leids Universitair Medisch Centrum
Schindler, Katja
United States, New York
Memorial Sloan-kettering Cancer Center
Austria, Vienna
Medizinische Universität Wien Universitätsklinik Für Dermatologie
Epstein, Joel Brian
United States, Los Angeles
Cedars-sinai Medical Center
Choi, Jennifer Nam Nam
United States, New Haven
Yale School of Medicine
Beamer, Laura
United States, Dekalb
Northern Illinois University
Roeland, Eric J.
United States, La Jolla
Moores Cancer Center
Russi, Elvio G.
Italy, Cuneo
S. Croce and Carle Teaching Hospital
Bensadoun, Réné Jean J.
France, Nice
Centre de Haute Energie
Teo, Yi Ling
Singapore, Singapore City
National University of Singapore
Chan, Raymond J.
Australia, Brisbane
Queensland University of Technology
Shih, Vivianne
Singapore, Singapore City
National Cancer Centre, Singapore
Bryce, Jane
Italy, Naples
National Cancer Institute
Raber-Durlacher, Judith
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Gerber, Peter Arne
Germany, Dusseldorf
Heinrich-heine-universität Düsseldorf
Freytes, César O.
United States, San Antonio
University of Texas Health Science Center at San Antonio
Rapoport, Bernardo L.
South Africa, Johannesburg
Medical Oncology Centre of Rosebank
LeBoeuf, Nicole R.
United States, Boston
Dana-farber Cancer Institute
Sibaud, Vincent
France, Toulouse
Cancer University Institute of Toulouse Oncopole
Lacouture, Mario E.
United States, New York
Memorial Sloan-kettering Cancer Center
Statistics
Citations: 27
Authors: 22
Affiliations: 21
Identifiers
Doi:
10.1007/s00520-014-2564-x
ISSN:
09414355
e-ISSN:
14337339
Research Areas
Cancer
Disability
Health System And Policy
Study Approach
Systematic review